EAM
CTMX icon

Exane Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Exane Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,568
Closed -$200K – 20
2020
Q4 		$200K Sell
30,568
-33,252
-52% -$238K 0.14% 18
2020
Q3 		$424K Sell
63,820
-24,056
-27% -$178K 0.28% 19
2020
Q2 		$732K Hold
87,876
– – 0.75% 16
2020
Q1 		$674K Hold
87,876
– – 1.31% 10
2019
Q4 		$730K Buy
87,876
+33,811
+63% +$228K 0.9% 24
2019
Q3 		$399K Sell
54,065
-52,935
-49% -$522K 0.31% 23
2019
Q2 		$1.2M Buy
107,000
+7,000
+7% +$73.4K 0.53% 44
2019
Q1 		$1.07M Buy
100,000
+50,000
+100% +$739K 0.52% 37
2018
Q4 		$755K Buy
50,000
+22,100
+79% +$328K 0.44% 34
2018
Q3 		$516K Buy
27,900
+5,700
+26% +$130K 0.16% 52
2018
Q2 		$507K Buy
22,200
+4,200
+23% +$107K 0.22% 45
2018
Q1 		$512K Buy
18,000
+9,000
+100% +$257K 0.15% 50
2017
Q4 		$190K Buy
+9,000
New +$187K 0.06% 46

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Exane Asset Management's CTMX Position: Q1 2021 in Review

Exane Asset Management sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 30,568 shares — an estimated $200K sold.

Exane Asset Management first reported a position in CTMX in Q4 2017 and held it in 13 quarters. The position peaked at $1.2M in Q2 2019. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

  • Exane Asset Management reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Exane Asset Management sold 30,568 CytomX Therapeutics shares in Q1 2021, an estimated $200K.
  • Exane Asset Management first reported a position in CytomX Therapeutics in Q4 2017 and held it in 13 quarters.
  • Exane Asset Management's CytomX Therapeutics position peaked at $1.2M in Q2 2019.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Exane Asset Management's 13F filing for Q1 2021, filed 21 Apr 2021.